文献速递浆细胞疾病造血干细胞移植与细胞治疗

CyBorD-DARA 作为多发性骨髓瘤初始诱导高效并增强 ADCP:16-BCNI-001/CTRIAL-IE 16-02 研究初步结果

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
PubMed 文献 · Blood Adv · 2019-01-01

这项 1b 期研究评估达雷妥尤单抗(DARA,16 mg/kg)联合每周皮下硼替佐米、环磷酰胺、地塞米松(CyBorD-DARA)作为自体干细胞移植(ASCT)前初始诱导的安全性和初步疗效。18 例初治多发性骨髓瘤患者入组,未出现剂量限制性毒性,3 或 4 级感染或中性粒细胞减少发生率<10%;意向治疗下 94% 达≥非常好的部分缓解,44% 达≥完全缓解。

要点

  • DARA 16 mg/kg 联合每周皮下硼替佐米、环磷酰胺、地塞米松作为 ASCT 前初始诱导,未出现剂量限制性毒性。
  • 意向治疗下 94% 患者达≥非常好的部分缓解,44% 达≥完全缓解。
  • 体外分析提示 CyBorD-DARA 诱导巨噬细胞介导的抗体依赖性细胞吞噬(ADCP)活化。

核心结论

  • CyBorD-DARA 作为多发性骨髓瘤初始诱导方案具有较强活性,且可增强巨噬细胞介导的抗体依赖性细胞吞噬。
  • 该方案未出现剂量限制性毒性,3 或 4 级感染或中性粒细胞减少发生率<10%。

研究设计与样本

  • 1b 期研究,评估 DARA(16 mg/kg)联合每周皮下硼替佐米(1.3-1.5 mg/m2)、环磷酰胺(150-300 mg/m2)、地塞米松(40 mg)作为 ASCT 前初始诱导的安全性和初步疗效及潜在机制。
  • 入组 18 例年龄≤70 岁、需治疗且无显著合并症的初治多发性骨髓瘤患者;中位年龄 56 岁(范围 32-66 岁),全部 ECOG 体能状态≤1。
  • ISS 分期 I、II、III 期分别占 78%、17%、6%;28% 患者具有高危遗传学特征。
  • 试验注册号 NCT02955810。

主要发现

  • 未出现剂量限制性毒性,3 或 4 级感染或中性粒细胞减少发生率<10%。
  • 意向治疗下 94% 患者达≥非常好的部分缓解,44% 患者达≥完全缓解。
  • 15 例接受 ASCT 的患者中 14 例可评估疗效,全部 14 例至少达非常好的部分缓解,其中 8 例(57%)达完全缓解。
  • ASCT 后 12 例可进行微小残留病分析的患者中 10 例(83%)在 10-5 灵敏度下经二代测序检测为阴性(意向治疗/全研究人群为 56%)。
  • 患者样本流式细胞分析提示 CyBorD-DARA 诱导巨噬细胞介导的抗体依赖性细胞吞噬活化。

关键数值与推荐

  • DARA 剂量为 16 mg/kg。
  • 硼替佐米为每周皮下 1.3-1.5 mg/m2。
  • 环磷酰胺为 150-300 mg/m2,地塞米松为 40 mg。
  • 微小残留病阴性定义为二代测序在 10-5 灵敏度下检测阴性。

临床怎么用

  • 对于年龄≤70 岁、无显著合并症、需治疗的初治多发性骨髓瘤患者,CyBorD-DARA 可作为 ASCT 前初始诱导方案。
  • 该方案在此 1b 期研究中未出现剂量限制性毒性,3 或 4 级感染或中性粒细胞减少发生率<10%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2), cyclophosphamide (150-300 mg/m2), and dexamethasone (40 mg) (CyBorD DARA) as initial induction before autologous stem cell transplantation (ASCT). Eligible patients were ≤70 years of age with untreated MM requiring treatment and who lacked significant comorbidities. A total of 18 patients were enrolled. Their median age was 56 years (range, 32-66 years), and all patients had Eastern Cooperative Oncology Group performance status ≤1. The International Staging System stages were I, II, and III in 78%, 17%, and 6% of patients, respectively; 28% of patients had high-risk genetic features. There was no dose-limiting toxicity, and the incidence of grade 3 or 4 infection or neutropenia was <10%. On an intention-to-treat basis, 94% achieved ≥very good partial response with ≥complete response in 44% of patients. Among 14 of 15 patients who underwent ASCT and were evaluable for response, all 14 achieved at least very good partial response, with 8 (57%) of 14 achieving complete response. After ASCT, 10 (83%) of 12 patients in whom minimal residual disease analysis was possible were negative at a sensitivity of 10-5 (56% on intention-to-treat/whole study population) according to next-generation sequencing. Flow cytometry analysis of patient samples indicated CyBorD DARA induced activation of macrophage-mediated antibody-dependent cellular phagocytosis. This trial was registered at www.clinicaltrials.gov as #NCT02955810.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. O'Dwyer M, Henderson R, Naicker SD, et al. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019. PMID: 31201169. doi:10.1182/bloodadvances.2019000010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。